Journal of Intensive Care Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baddigam, K.
Right arrow Articles by Tobias, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baddigam, K.
Right arrow Articles by Tobias, J. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Intensive Care Medicine, Vol. 20, No. 2, 118-123 (2005)
DOI: 10.1177/0885066604273481

Dexmedetomidine in the Treatment of Withdrawal Syndromes in Cardiothoracic Surgery Patients

Krishna Baddigam, MD

Department of Anesthesiology, University of Missouri, Columbia, Missouri

Pierantonio Russo, MD

Department of Cardiothoracic Surgery, University of Missouri, Columbia, Missouri

JoAnne Russo, RN

Department of Nursing, University of Missouri, Columbia, Missouri

Joseph D. Tobias, MD

Departments of Anesthesiology, Pediatrics, University of Missouri, Columbia, Missouri

Dexmedetomidine (Precedex, Abbott Laboratories, Abbott Park, IL) is an• 2adrenergic agonist that possesses a high ratio of specificity for the• 2versus the• 1receptor. It is currently approved for the provision of sedation during mechanical ventilation in adults. Given previous experience with clonidine for the treatment of substance withdrawal and the preliminary anecdotal experience with dexmedetomidine, it appears that dexmedetomidine may be a useful agent for treatment of substance withdrawal in the intensive care setting. The authors present their experience with the use of dexmedetomidine to control withdrawal behavior in 3 patients following cardiothoracic surgery. Previous reports regarding the use of dexmedetomidine to treat withdrawal and its potential application in this clinical arena are reviewed.

Key Words: dexmedetomidine • opioid withdrawal • intensive care unit sedation • abstinence syndromes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
D. V. Menon, Z. Wang, P. J. Fadel, D. Arbique, D. Leonard, J.-L. Li, R. G. Victor, and W. Vongpatanasin
Central Sympatholysis as a Novel Countermeasure for Cocaine-Induced Sympathetic Activation and Vasoconstriction in Humans
J. Am. Coll. Cardiol., August 14, 2007; 50(7): 626 - 633.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. T Gerlach and J. F Dasta
Dexmedetomidine: An Updated Review
Ann. Pharmacother., February 1, 2007; 41(2): 245 - 252.
[Abstract] [Full Text] [PDF]